Karen L Lindsay
Affiliation: University of Southern California
- Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysisStephen J Polyak
Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
Virol J 2:41. 2005..QS diversity and complexity were quantified using heteroduplex mobility assays (HMA)...
- Introduction to therapy of hepatitis CKaren L Lindsay
Keck School of Medicine, University of Southern California, Los Angeles 90033, CA, USA
Hepatology 36:S114-20. 2002....
- Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis CKaren L Lindsay
Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
Clin Gastroenterol Hepatol 6:234-41. 2008..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
- Outcome of sustained virological responders with histologically advanced chronic hepatitis CTimothy R Morgan
Division of Gastroenterology, University of California Irvine, Irvine, CA, USA
Hepatology 52:833-44. 2010..15, 95% CI = 0.06-0.38) or HCC (HR = 0.19, 95% CI = 0.04-0.80) was significant for SVR compared to NR. Laboratory tests related to liver disease severity improved following SVR...
- Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapyKung Chia Young
Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90089 9094, USA
Hepatology 38:869-78. 2003..Furthermore, the selection of an RBV-resistant variant with a single amino acid substitution in NS5B suggested that RBV may directly interact with HCV RNA polymerase, thus interfering with its enzymatic activity...
- Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenesKeigo Machida
Department of Molecular Microbiology and Immunology, University of Southern California Keck School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90033, USA
Proc Natl Acad Sci U S A 101:4262-7. 2004..These results indicate that HCV induces a mutator phenotype and may transform cells by a hit-and-run mechanism. This finding provides a mechanism of oncogenesis for an RNA virus...
- More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosisSumita Verma
Division of Gastrointestinal and Liver Diseases, Hepatitis Research and Treatment Center, Los Angeles, California, USA
Am J Gastroenterol 101:1817-23. 2006..We sought to assess whether Hispanics have more advanced hepatitis C virus (HCV)-related liver disease than non-Hispanic whites (NHW) and to identify contributory factors...
- Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infectionVicky M H Sung
Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
J Virol 77:2134-46. 2003..HCV-infected cell lines show significantly enhanced apoptosis. These B-cell lines provide a reproducible cell culture system for studying the complete replication cycle and biology of HCV infections...
- Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis CChihiro Morishima
Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
Hepatology 48:1412-9. 2008..With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (P < 0.0001)...
- Inadequate numbersKaren L Lindsay
Can Fam Physician 53:401; author reply 401-2. 2007
- Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis CRobert J Fontana
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0362, USA
Hepatology 45:1154-63. 2007..Nonetheless, the frequency of cognitive impairment did not increase during the first 24 weeks of treatment in 177 patients (34% versus 32%, P=0.64) nor in the 57 patients completing 48 weeks of treatment (P=0.48, ANOVA)...
- Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trialAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
Clin Gastroenterol Hepatol 5:245-54. 2007....
- Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis CMitchell L Shiffman
Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
Gastroenterology 132:103-12. 2007..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment...
- HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trialChihiro Morishima
Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
Hepatology 44:360-7. 2006..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did...
- Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) TrialLeonard B Seeff
Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Hepatology 47:605-12. 2008..Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C...
- Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis CChihiro Morishima
Department of Laboratory Medicine and Pediatrics, University of Washington, Seattle, USA
J Infect Dis 193:931-40. 2006..Thus, in patients with advanced hepatic fibrosis due to HCV infection, pretreatment HCV-specific immune responses and increased QS variability appear to hinder viral clearance by pegylated IFN- alpha 2a and ribavirin combination therapy...
- Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis CJohn G McHutchison
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
Gastroenterology 123:1061-9. 2002..We evaluated the impact of adherence to combination therapy with interferon or peginterferon plus ribavirin in chronic hepatitis C patients...
- Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatmentMitchell L Shiffman
Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
Gastroenterology 126:1015-23; discussion 947. 2004..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
- Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespondersWilliam M Lee
Control Clin Trials 25:472-92. 2004..The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity...
- Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis CAlan Lee Rothman
Center for Infectious Disease and Vaccine Research and Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
Hepatology 41:617-25. 2005....
- Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohortAnna S F Lok
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
Hepatology 42:282-92. 2005..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC...
- Cognitive reserve and neuropsychological functioning in patients infected with hepatitis CLinas A Bieliauskas
Neuropsychology Section, Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Michigan 48105, USA
J Int Neuropsychol Soc 13:687-92. 2007..It is important to account for CRS when assessing cognitive findings in large-scale clinical trials...
- Treatment of chronic hepatitis C infection: one step at a timeGary L Davis
Division of Hepatology, Baylor University Medical Center and Baylor Regional Transplant Institute, Dallas, Texas 75246, USA
Lancet Infect Dis 5:524-6. 2005..Drugs that directly act on the replicative machinery of the virus-protease and polymerase inhibitors-are under development and entering clinical trials in human beings...
- Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C TrialAdrian M Di Bisceglie
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
J Hepatol 43:434-41. 2005..We assessed serum AFP among patients with chronic hepatitis C and advanced fibrosis to establish predictors of AFP elevations and changes with antiviral therapy...
- Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trialRobert J Fontana
Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109 0362, USA
J Hepatol 43:614-22. 2005..The aim of this study was to determine the frequency, type, and severity of cognitive impairment in a large group of CHC patients with advanced fibrosis...
- Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosisLinas A Bieliauskas
University of Michigan Medical Center, Ann Arbor, MI, USA
J Clin Exp Neuropsychol 28:1346-61. 2006..There was a significant correlation between cognitive impairment and self-reported depression...
- Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosisBurton Combes
The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9151, USA
Hepatology 42:1184-93. 2005..In conclusion, methotrexate when added to UDCA for a median period of 7.6 years had no effect on the course of PBC treated with UDCA alone...